An injectable gel of cisplatin/epinephrine effectively reduces tumor burden and ameliorates tumor symptoms in patients with squamous cell carcinoma of the head and neck, according to the results of two identically designed phase III trials.
Dr. Barry L. Wenig from Northwestern University Medical School, Evanston, Illinois, and colleagues randomly assigned 179 patients with recurrent or refractory squamous cell carcinoma of the head or neck to cisplatin/epinephrine injectable gel or placebo
תגובות רוצה להצטרף לדיון?
יש להתחבר כדי להגיב.
התחבראין תגובות עדיין. היה הראשון להגיב!